Two Sigma Securities LLC Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR

Two Sigma Securities LLC purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,256 shares of the biotechnology company’s stock, valued at approximately $917,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC lifted its holdings in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares in the last quarter. Tsfg LLC acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $25,000. Optiver Holding B.V. increased its holdings in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares in the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth about $39,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $82.39 on Tuesday. The stock has a market capitalization of $11.61 billion, a PE ratio of -36.62 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $21.61 and a 1-year high of $95.49. The firm has a fifty day simple moving average of $83.65 and a 200 day simple moving average of $73.76. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.26) earnings per share. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current fiscal year.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ARWR. Piper Sandler reiterated an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They set a “buy” rating and a $98.00 target price for the company. Leerink Partners upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. JPMorgan Chase & Co. increased their price objective on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, B. Riley Financial boosted their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $98.42.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.